Precision and personalized medicine: deals decreased significantly in clinical trials in H2 2021

In the second half of 2021 the number of deals relating to precision and personalized medicine decreased significantly by 54.1% from the same period in 2020.

This marks an acceleration in growth from the 86.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to precision and personalized...